Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-pd-1/pd-l1 immunotherapy in advanced nsclc patients

HIGHLIGHTS

• who: Benito Farina from the A total of , patients with pathologically confirmed stage IV NSCLC treated with anti-PD-1/PD-, monoclonal antibodies from January , to December , were retrospectively collected at the Hospital Universitario Fundaciu00f3n Jimu00e9nez Du00edaz (FJD, patients) and Clu00ednica Universidad de Navarra (CUN, patients)Their institutional review boards approved the study, and informed consent was collected accordingly. Inclusion criteria were: (a) confirmed advanced NSCLC have published the Article: Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients, in the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.